TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01917604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open exposure
Description: the open surgical methods of exposing the canine is compared with control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed exposure
Description: closed exposure is compared with control
Study: NCT05460637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No BS just Fitness
Description: The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
Study: NCT05258799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Study: NCT05636982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecare-based intervention program
Description: A 3-month telecare-based intervention program
Study: NCT04858360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emla 1 hour
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA 3 hours
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle cream for 1 hour
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle cream for 3 hours
Description: At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
Study: NCT05056571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
Study: NCT06200272

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Germ and Carob Molasses Pulp added standard whole wheat breads
Description: Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
Study: NCT05692219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine
Description: 6 weeks booklet-delivered multicomponent lifestyle medicine intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 6 weeks booklet-delivered self-help cognitive behavioral therapy
Study: NCT05822128

Intervention type: OTHER
Intervention: Test of an alternative Epworth Sleepiness Scale ESS-ALT in French
Description: Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
Study: NCT05035797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary rehabilitation
Description: Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
Study: NCT05313646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 1 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
Study: NCT05010668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cryoablation
Description: Cryoablation treatment starts at day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT06490601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide and hydroxyurea
Description: Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile.
Study: NCT05586412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation
Description: Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation
Description: Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagus nerve stimulation
Description: Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
Study: NCT05216198

Intervention type: OTHER
Intervention: Check of the different exams performed at the emergencies
Description: Check of the different exams performed at the emergencies
Study: NCT05632380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
Study: NCT05313646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 2 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: batch 3 of Ad5-nCoV
Description: The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
Study: NCT05632380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
Study: NCT04352738

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)
Description: Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)
Description: Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)
Description: Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
Study: NCT06147323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Healthy Diet
Description: Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Seaweed Group
Description: Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diet Group
Description: Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
Study: NCT05749497

Intervention type: OTHER
Intervention: NCRT+TME
Description: The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
Study: NCT05119569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: Fenebrutinib will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06351397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR)
Description: Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study: NCT06548594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Neurostimulation
Description: Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
Study: NCT05611853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN301
Description: BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN301
Description: BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN301
Description: BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
Study: NCT05468515

Intervention type: DIAGNOSTIC_TEST
Intervention: pulse oxygen saturation
Description: preductal oxygen saturation

Intervention type: DIAGNOSTIC_TEST
Intervention: pulse oxygen saturation
Description: preductal oxygen saturation
Study: NCT06434363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by vein (IV)
Study: NCT05539196

Intervention type: DEVICE
Intervention: Exablate Pallidotomy, Unilateral
Description: Unilateral pallidotomy using focused ultrasound for the treatment of Parkinson's Disease with medication-refractory moderate to severe motor complications.
Study: NCT05276843

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Qigong exercise program
Description: Qigong is a low-impact, weight-bearing exercise characterized by gentle movements designed to dissipate force throughout the body while the subject changes poses, with well-coordinated sequences of both isometric and isotonic segmental movements in the trunk and 4 extremities.
Study: NCT06384378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 11C-ER176
Description: ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation.
Study: NCT04767360

Intervention type: DEVICE
Group type: OTHER
Intervention: Bioness-300
Description: Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
Study: NCT05064644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product that contains plant stanol ester
Description: Product with active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Product without active ingredient
Study: NCT06437119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Compound plant nutrients
Description: The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo with an indistinguishable appearance and color.
Study: NCT06241729

Intervention type: OTHER
Intervention: Algorithms to predict the probability of a primary refractory state
Description: Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
Study: NCT04981353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae plane block at T11
Description: A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
Study: NCT05582187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: a single dose of fosmanogepix administered by mouth under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: a single dose of fosmanogepix administered by mouth under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: a single dose of fosmanogepix administered by mouth under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmanogepix
Description: a single dose of fosmanogepix administered by mouth under fasted conditions
Study: NCT06413745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811
Study: NCT05626218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
Study: NCT05501067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tai chi exercise
Description: specific tai chi exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: no intervention
Study: NCT03271749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections
Description: The PROSM guidelines is described previously in study description